References
- Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. CNS Drugs. 2011;25(5):383–399.
- Young SL, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353–362.
- Iversen TSJ, Steen NE, Dieset I, et al. Side effect burden of antipsychotic drugs in real life – impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263–271.
- Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
- Boskailo E, Malkoc A, McCurry DB, et al. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: a retrospective cohort study. Acta Med Acad. 2017;46(2):133–144.
- Essock SM, Schooler NR, Stroup TS, et al., Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702–708.
- Tani H, Uchida H, Suzuki T, et al. Interventions to reduce antipsychotic polypharmacy: a systematic review. Schizophr Res. 2013;143(1):215–220.
- National Directorate of Health. National Guideline for the Diagnosis, Teatment and Follow-up of Persons with Psychotic Disorders. Oslo: National Directorate of Health; 2013.
- Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014;19(5):439–448.
- Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499–507.
- Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35(3):661–681.
- Castberg I, Spigset O. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Ther Drug Monit. 2008;30(5):597–603.
- Centorrino F, Cincotta SL, Talamo A, et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry. 2008;49(1):65–69.
- Connolly A, Rogers P, Taylor D. Antipsychotic prescribing quality and ethnicity: a study of hospitalized patients in south east London. J Psychopharmacol. 2007;21(2):191–197.
- De Hert M, Wampers M, Peuskens J. Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract. 2006;10(4):285–290.
- Paton C, Barnes TR, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192(6):435–439.
- Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28.
- Brunette MF, Cotes RO, de Nesnera A, et al. Use of academic detailing with audit and feedback to improve antipsychotic pharmacotherapy. Psychiatr Serv. 2018;69(9):1021–1028.
- Berrouiguet S, Barrigon ML, Brandt SA, et al. Ecological assessment of clinicians’ antipsychotic prescription habits in psychiatric inpatients: a novel web- and mobile phone-based prototype for a dynamic clinical decision support system. J Med Internet Res. 2017;19(1):e25.
- Mace S, Taylor D. Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme. Ther Adv Psychopharmacol. 2015;5(1):4–12.
- Johnsen E, Jørgensen HA, Svingen GF. Practice regarding antipsychotic therapy: a cross-sectional survey in two Norwegian hospitals. Nord J Psychiatry. 2004;58(4):313–317.
- Sneider B, Pristed SG, Correll CU, et al. Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: a nation-wide pharmacoepidemiological study. Eur Neuropsychopharmacol. 2015;25(10):1669–1676.
- Højlund M, Elliott AF, Madsen NJ, et al. Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia. Nord J Psychiatry. 2017;71(8):598–604.
- Heald A, Livingston M, Yung A, et al. Prescribing in schizophrenia and psychosis: increasing polypharmacy over time. Hum Psychopharmacol Clin Exp. 2017;32(2):e2579.